GPT and hepatocellular carcinoma: A phase III clinical study comparing the efficacy and safety of Tislelizumab and sorafenib in the treatment of hepatocellular carcinoma reported that elevated ALT, AST, and serum bilirubin levels were the most common adverse reactions in the Tislelizumab group, which is consistent with our analysis (7).